L Norton

发表

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Potential innovations in scheduling of cancer chemotherapy.

L. Norton, L Norton, R Day, 1991, Important advances in oncology.

Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.

P Borgen, K Offit, J. Satagopan, 1999, Journal of the National Cancer Institute.

Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.

W Wood, L. Norton, D. Hayes, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of angiogenesis in lymph node metastases with outcome of breast cancer.

Anthony J. Guidi, D A Berry, D. Berry, 2000, Journal of the National Cancer Institute.

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

N S El Saghir, L Biganzoli, N Harbeck, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The AURORA initiative for metastatic breast cancer

C Sotiriou, C. Sotiriou, M. Dowsett, 2014, British Journal of Cancer.

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

K S Panageas, G. Hortobagyi, C. Hudis, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

L. Norton, J. Baselga, J. Albanell, 1998, Cancer research.

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

D Tripathy, C. Hudis, L. Norton, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline BRCA1 185delAG mutations in Jewish women with breast cancer

K Offit, A Schluger, M. Skolnick, 1996, The Lancet.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-

L. Norton, N. Rosen, D. Solit, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Metastatic breast cancer. Length and quality of life.

L. Norton, L Norton, 1991, The New England journal of medicine.

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

R. Bast, L. Norton, C. Desch, 1996, Journal of the National Cancer Institute.

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

L. Norton, J. Baselga, A. Seidman, 1997, Oncology.

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

L. Norton, J. Baselga, D. Pfister, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

E. Venkatraman, L. Norton, R. Barakat, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

T J Yao, C. Hudis, L. Norton, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations.

M. Wigler, J. Alexander, R. Lucito, 2000, Genome research.